X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27539) 27539
Newspaper Article (1505) 1505
Newsletter (822) 822
Magazine Article (309) 309
Book Chapter (76) 76
Trade Publication Article (23) 23
Dissertation (18) 18
Transcript (14) 14
Book Review (11) 11
Publication (9) 9
Reference (8) 8
Conference Proceeding (7) 7
Web Resource (7) 7
Streaming Video (5) 5
Government Document (4) 4
Report (4) 4
Pamphlet (2) 2
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19712) 19712
aspirin (17182) 17182
male (12486) 12486
female (11507) 11507
aspirin - administration & dosage (9376) 9376
middle aged (7570) 7570
aged (6588) 6588
aspirin - therapeutic use (6052) 6052
adult (5514) 5514
animals (4724) 4724
risk factors (4199) 4199
aspirin - adverse effects (3909) 3909
platelet aggregation inhibitors - administration & dosage (3857) 3857
aspirin - pharmacology (3633) 3633
cardiac & cardiovascular systems (3444) 3444
prevention (3399) 3399
platelet aggregation inhibitors - therapeutic use (3330) 3330
treatment outcome (3220) 3220
clopidogrel (3114) 3114
drug therapy, combination (3066) 3066
ticlopidine - analogs & derivatives (2955) 2955
pharmacology & pharmacy (2901) 2901
dosage and administration (2767) 2767
risk (2661) 2661
time factors (2580) 2580
drug therapy (2384) 2384
dose-response relationship, drug (2356) 2356
stroke (2344) 2344
research (2215) 2215
rats (2208) 2208
peripheral vascular disease (2183) 2183
medicine, general & internal (2166) 2166
care and treatment (2130) 2130
platelet aggregation inhibitors - adverse effects (2051) 2051
administration, oral (1982) 1982
aged, 80 and over (1898) 1898
low-dose aspirin (1879) 1879
hematology (1853) 1853
mortality (1850) 1850
therapy (1817) 1817
abridged index medicus (1812) 1812
thrombosis (1801) 1801
ticlopidine - administration & dosage (1765) 1765
platelet aggregation - drug effects (1732) 1732
analysis (1722) 1722
health aspects (1718) 1718
prospective studies (1686) 1686
heart attacks (1660) 1660
double-blind method (1613) 1613
anticoagulants (1605) 1605
surgery (1579) 1579
cardiovascular disease (1556) 1556
anti-inflammatory agents, non-steroidal - administration & dosage (1543) 1543
nonsteroidal antiinflammatory drugs (1508) 1508
ticlopidine - therapeutic use (1483) 1483
anticoagulants - administration & dosage (1459) 1459
pregnancy (1426) 1426
medicine & public health (1415) 1415
retrospective studies (1387) 1387
follow-up studies (1386) 1386
anti-inflammatory agents, non-steroidal - adverse effects (1360) 1360
anticoagulants - therapeutic use (1360) 1360
myocardial-infarction (1351) 1351
antiplatelet therapy (1294) 1294
patients (1267) 1267
blood platelets (1263) 1263
inhibition (1256) 1256
cardiology (1245) 1245
drug administration schedule (1228) 1228
blood platelets - drug effects (1225) 1225
acute coronary syndromes (1223) 1223
percutaneous coronary intervention (1203) 1203
warfarin (1192) 1192
inflammation (1153) 1153
disease (1137) 1137
adolescent (1135) 1135
studies (1124) 1124
risk assessment (1115) 1115
clinical trials (1113) 1113
anti-inflammatory agents, non-steroidal - therapeutic use (1099) 1099
platelet aggregation inhibitors - pharmacology (1093) 1093
cardiovascular diseases (1081) 1081
stents (1059) 1059
clinical trials as topic (1058) 1058
drug dosages (1057) 1057
medical research (1052) 1052
hemorrhage - chemically induced (1039) 1039
coronary heart disease (1034) 1034
randomized controlled trials as topic (1030) 1030
cardiac patients (1022) 1022
cancer (1020) 1020
mice (1016) 1016
drugs (1015) 1015
management (1015) 1015
complications and side effects (991) 991
internal medicine (967) 967
nonsteroidal anti-inflammatory drugs (957) 957
stroke - prevention & control (957) 957
oncology (942) 942
cardiovascular (939) 939
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28540) 28540
German (697) 697
Japanese (417) 417
French (322) 322
Russian (250) 250
Spanish (159) 159
Italian (116) 116
Polish (90) 90
Chinese (88) 88
Portuguese (60) 60
Danish (52) 52
Norwegian (41) 41
Dutch (38) 38
Swedish (30) 30
Czech (27) 27
Hungarian (25) 25
Turkish (17) 17
Korean (15) 15
Ukrainian (9) 9
Romanian (7) 7
Serbian (7) 7
Bulgarian (6) 6
Hebrew (6) 6
Slovak (6) 6
Lithuanian (5) 5
Croatian (4) 4
Finnish (4) 4
Persian (3) 3
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American journal of medicine, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | CYTOCHROME-P450 | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents
Journal Article
Stroke (1970), ISSN 1524-4628, 2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | CYTOCHROME-P450 | MYOCARDIAL-INFARCTION | ACID SUPPRESSION | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | LOW-DOSE ASPIRIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DISEASE | PRASUGREL | GASTROENTEROLOGY & HEPATOLOGY | PEPTIC-ULCERS | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 22, pp. 2100 - 2109
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 3, p. CD009868
Background Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary... 
Blood Pressure | Drugs | A.1 Drugs | Anticholesteremic Agents | Aspirin | Cardiovascular Diseases | Heart disease prevention | Costs | A.1.3 Other | Placebo Effect | A. Cardiovascular Disease: Primary Prevention | Insurance medicine | Cause of Death | Cholesterol | Randomized Controlled Trials as Topic | Prevention | Platelet Aggregation Inhibitors | Antihypertensive Agents | Heart & circulation | Medicine General & Introductory Medical Sciences | Drug Combinations | POLYPILL-BASED STRATEGY | Humans | Antihypertensive Agents [administration & dosage] | Anticholesteremic Agents [administration & dosage] | Cardiovascular Diseases [mortality; prevention & control] | RANDOMIZED CONTROLLED-TRIAL | PROACTIVE MULTIFACTORIAL INTERVENTION | Aspirin [administration & dosage] | USUAL CARE | MEDICINE, GENERAL & INTERNAL | Platelet Aggregation Inhibitors [administration & dosage] | HIGH-RISK | DOUBLE-BLIND | SINGLE-PILL COMBINATION | BLOOD-PRESSURE CONTROL | PLACEBO-CONTROLLED TRIAL | CORONARY-HEART-DISEASE | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Anticholesteremic Agents - adverse effects | Antihypertensive Agents - adverse effects | Aspirin - administration & dosage | Aspirin - adverse effects | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Platelet Aggregation Inhibitors - adverse effects
Journal Article